INTERVENTIONAL PULMONOLOGY CORPORATE AND REGIONAL PRESS RELEASES

Please find below a list of our press releases.

21 Aug 2017

BTG and SIO expand Immuno-Oncology / Interventional Oncology grant programme

BTG plc (LSE: BTG), a global specialist healthcare company, and the Society of Interventional Oncology (SIO), an international organisation working to nurture and support interventional oncology worldwide, have expanded their commitment to the Immuno-Oncology / Interventional Oncology research grant programme, by announcing a second round of funding available to investigators.

14 Dec 2015

BTG Announces Positive Data from RENEW study of PneumRx® Coils

BTG plc (LSE: BTG), the specialist healthcare company, today announces the successful outcome of the RENEW study, the pivotal US randomised controlled clinical trial comparing the safety and efficacy of the PneumRx endobronchial coil implant (EBCI) with a medical therapy control group in patients with homogeneous and/or heterogeneous severe emphysema.

19 May 2015

REVOLENS study of PneumRx® endobronchial coils in severe emphysema meets primary endpoint

BTG plc (LSE: BTG), the specialist healthcare company, notes the presentation of top line data showing that REVOLENS, a randomized, controlled trial sponsored by the French Ministry of Health, met its primary endpoint.

8 Jan 2015

BTG plc: Completion of the acquisition of PneumRx Inc

BTG plc announced on 4 December 2014 that it had entered into an agreement to buy PneumRx Inc, a growing interventional pulmonology business.

4 Dec 2014

Acquisition of PneumRx

BTG Plc is pleased to announce that it has entered into an agreement to acquire PneumRx Inc (PneumRx), a growing interventional pulmonology business.

Interventional Pulmonology